All News

child.guttate.psoriasis

Psoriasis and Nonalcoholic Fatty Liver Disease

Jack Cush, MD

A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD).

Read Article
RheumNow Podcast square

The Inflammation Reflex (5.20.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

Jack Cush, MD

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
TNRPSA,0426

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Jack Cush, MD

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article
Liver,hepatic,red

Arthritis Predicts Hepatic Fibrosis in Hemochromatosis

Jack Cush, MD

Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis. 

Read Article
colitis.jpg

Spondyloarthritis in Early Crohn's Disease

Jack Cush, MD

Analysis of a German Crohn's disease cohort finds that in patients with early Crohn’s disease (CD), spondyloarthritis was present in nearly one out of five patients and was associated with HLA-B27 positivity and a highly active CD.

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

Jack Cush, MD

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen journal articles, news reports and questions + cases.

Read Article
Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth

Links:

Dr. John Cush RheumNow ( View Tweet)
Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9

Links:

Eric Topol EricTopol ( View Tweet)
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/iGyAmCoO96

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of PCP Dx irritable bowel dz; 459 randomised to 8 weeks of oral antispasmodics or diet (low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP). Better responses with diet (71% vs 61%; p=0.03). Better adherence w/ diet. https://t.co/gmn45yQmuB https://t.co/8SP5Vfx71z

Links:

Dr. John Cush RheumNow ( View Tweet)
ABP 654 is a Ustekinumab (anti-IL-12/23) biosimilar from Amgen - 563 pt, phase 3 trial shown to be equivalent to originator in mod- severe plaque psoriasis (no meaningful differences). ABP 654 is also being developed for Crohns & UC. https://t.co/vDNfMXCWcC

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: 520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/PxrabHROPy https://t.co/UAw51Hb5vU

Links:

Dr. John Cush RheumNow ( View Tweet)
Avacopan efficacy in renal failure in AAV. Appears to have benefit in renal disease that is more marked the more severe the disease is #Vasculitis22 https://t.co/3zsxjTLj62
Richard Conway RichardPAConway ( View Tweet)
211 pts presenting w/ hot swollen joint to the ER; 28 w/ septic arthritis; pseudogout 32; gout 50; & others: 101. Predictors of Septic Arthritis: RA (OR 3.4); skin infx (OR 3.3); liver Dz (OR 9.9); knee involv (OR 3.5); immunosuppressive use (OR 3.5) https://t.co/uASovNVOWb https://t.co/Fq3obVDavm

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Environmental Pollutants Ups Autoimmune Disease Risk An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, CTDs and inflammatory bowel diseases (IBD). https://t.co/oKdgSZ2jAF https://t.co/WI7aShKR97

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×